THERAPY DOSSIER · th-9adeb9e780bd

Kynurenic acid (KYNA)

Nutraceutical

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: In trials, not approved
ChEMBL record: CHEMBL299155 ↗
ChEMBL max phase: 1 / 4 (development scale, not regulatory approval)
Synonyms: Kynurenic acid; Transtorine
Note: Not recorded

Clinical trials 2

1 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT06807021 ↗Injury indicationPHASE2/PHASE3recruiting

Topical FS2 (0.5%) for Mitigation of Cutaneous Scarring in Skin Graft/Donor Sites in Burn Patients

Burn Scar · Burn Wound

Enrolment: 70 · Results not recorded

NCT02340325 ↗PHASE1completed

Safety of Topically Delivered FS2 (kynurenic acid cream) in Humans, Phase 1

Cicatrix · Hypertrophic Scar · Keloid

Enrolment: 20 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 30327755 ↗2018Reported benefit

Kynurenic Acid Protects against Thioacetamide-Induced Liver Injury in Rats.

RatChemical/toxinWistarMalen = n=8 per group, four groupsIntraperitoneal500 mg/kg body weight30 minutes before thioacetamide administration (pretreatment)

Model: Single intraperitoneal thioacetamide injection (150 mg/kg body weight) inducing acute liver injury, assessed 24 h later

Kynurenic acid pretreatment prevented the thioacetamide-induced rise in AST (316.3 to 185.6 U/L) and ALT (90.2 to 57.8 U/L), restored liver kynurenic acid content, partly preserved thiol groups (36.3 to 61.5 mmol/mg protein), abolished the increases in MDA + 4-HNE, myeloperoxidase and TNF-alpha (39…

Extraction: extract · Supplied extraction confidence: 0.95. Machine-extracted fields require source verification.

Loading the evidence…